Personalized immunotherapy with encapsulated cell technology: Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors

被引：0
|
作者：
Fernandez, E. [1 ]
Vernet, R. [2 ]
Charrier, E. [3 ]
Migliorini, D. M. [4 ]
Urwyler, M. [2 ]
Belkouch, M-C. [2 ]
Von Rohr, O. [5 ]
Saingier, V. [5 ]
Ancrenaz, V. [5 ]
Grandjean, N. [6 ]
Lafferma, E. [6 ]
Lavalliere, E. [6 ]
Rubin, O. [7 ]
Villard, J. [8 ]
Grogg, J. N. [9 ]
Mach, N. [10 ]
机构：
[1] HUG Hopitaux Univ Geneve, Dept Oncol, Geneva, Switzerland
[2] HUG Hopitaux Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland
[3] UNIGE Univ Geneve, Cell Based Immunotherapy Iab, Oncol, Ctr Med Univ CMU, Geneva, Switzerland
[4] Hop Univ Geneve HUG, Oncol, Geneva, Switzerland
[5] HUG Hop Univ Geneve, Cell based Immunotherapy Lab, Oncol, Geneva, Switzerland
[6] HUG Hop Univ Geneve, Clin Res Unit, Oncol, Geneva, Switzerland
[7] HUG Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland
[8] Hop Univ Geneve, Clin Cell Therapy Lab, Geneva, Switzerland
[9] MaxiVax SA, R&D, Geneva, Switzerland
[10] HUG Hop Univ Geneve, Oncol, Geneva, Switzerland
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.888
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
762P
引用
收藏
页码：S891 / S891
页数：1
相关论文
共 50 条
  • [21] MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results
    Migliorini, D.
    Vernet, R.
    Belkouch, M. C.
    Luy, P.
    Blaser, S.
    Ancrenaz, V.
    Blazek, N.
    Grandjean, N.
    Wasem, J.
    Janin, B.
    Harboe-Schmidt, P.
    Grogg, J.
    Bouche, N.
    Mach, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S114 - S114
  • [22] Safety and Efficacy of First-in-human Clinical Trial of Intrathecal Transplantation of Human Astrocytes (AstroRx) Derived from hESC in ALS Patients
    Izrael, Michal
    Gotkine, Marc
    Lerner, Yossef
    Slutsky, Guy Shalom
    Chebath, Judith
    Caraco, Yoseph
    Ben-Hur, Tamir
    Hasson, Arik
    Sonnenfeld, Tehila
    Revel, Michel
    MUSCLE & NERVE, 2022, 66 : S48 - S48
  • [23] PRELIMINARY SAFETY, PK/PD AND EFFICACY RESULTS FROM A FIRST-IN-HUMAN PHASE I/IIA CLINICAL TRIAL OF BNT411, A SYSTEMIC TOLL-LIKE RECEPTOR 7 AGONIST IN PATIENTS WITH SOLID TUMORS
    Symeonides, Stefan
    Mahalingam, Devalingam
    Chae, Young Kwang
    Calvo, Emiliano
    Miguel, Maria
    Arkenau, Hendrik-Tobias
    Garralda, Elena
    Galvao, Vladimir
    Mita, Alain
    Hassan, Hariz
    Baumhauer, Annette
    Voelker, Timo
    Kuehnle, Marie-Cristine
    Roesemann, Roman
    Strobl, Stefan
    Tuereci, Oezlem
    Sahin, Ugur
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A555 - A555
  • [24] First-in-Human Phase 1 Trial of Agarose Beads Containing Murine RENCA Cells in Advanced Solid Tumors
    Smith, Barry H.
    Parikh, Tapan
    Andrada, Zoe P.
    Fahey, Thomas J.
    Berman, Nathaniel
    Wiles, Madeline
    Nazarian, Angelica
    Thomas, Joanne
    Arreglado, Anna
    Akahoho, Eugene
    Wolf, David J.
    Levine, Daniel M.
    Parker, Thomas S.
    Gazda, Lawrence S.
    Ocean, Allyson J.
    CANCER GROWTH AND METASTASIS, 2016, 9
  • [25] Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial
    Noda, Toshiyuki
    Nishigaki, Kazuhiko
    Minatoguchi, Shinya
    CIRCULATION JOURNAL, 2020, 84 (07) : 1189 - +
  • [26] First-in-human (FIH) trial evaluating immune activation and safety of PIN-2 administered intravenously to patients with advanced solid tumors.
    Bier, Colin
    Millward, Michael
    Kotasek, Dusan
    Gorelick, Kenneth J.
    Goldberg, Joshua Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] RESULTS OF A FIRST-IN-HUMAN PHASE I STUDY OF THE ALK INHIBITOR LDK378 IN ADVANCED SOLID TUMORS
    Shaw, A. T.
    Camidge, D. R.
    Felip, E.
    Sharma, S.
    Tan, D. S. W.
    Kim, D.
    De Pas, T.
    Vansteenkiste, J. F.
    Santoro, A.
    Liu, G.
    Goldwasser, M.
    Dai, D.
    Boral, A. L.
    Mehra, R.
    ANNALS OF ONCOLOGY, 2012, 23 : 153 - 153
  • [28] Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
    Lin, C-C.
    Schneider, R.
    Gutierrez, M.
    Shen, L.
    Chung, K.
    Doroshow, D. B.
    Gao, B.
    Millward, M.
    Hsieh, C-Y.
    Xu, C.
    Cai, S. X.
    Tian, Y. E.
    Liu, L.
    Shen, C.
    Tan, Y.
    He, Y.
    Zhang, C.
    Li, L.
    Ma, M.
    Xu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S503 - S504
  • [29] First-in-human study with ARQ 092, a novel pan AKT-inhibitor: Results from the advanced solid tumors cohorts.
    Saleh, Mansoor
    Papadopoulos, Kyri
    Arabnia, Alireza
    Patnaik, Amita
    Stein, Robin M.
    Cattaneo, Federica
    Abbadessa, Giovanni
    Greenberg, Jonathan
    Warren, Stephen
    Tolcher, Anthony
    CANCER RESEARCH, 2013, 73 (08)
  • [30] First-in-human trial of intravenous MEDI9253, an oncolytic virus, in combination with durvalumab in patients with advanced solid tumors
    Purroy, Noelia
    Durham, Nicholas
    Phillips, Marc
    Hattersley, Maureen M.
    Jung, Lindsey
    Davar, Diwakar
    Zamarin, Dmitriy
    Johanns, Tanner M.
    Puzanov, Igor
    CANCER RESEARCH, 2022, 82 (12)
12345